Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.60 Consensus Price Target from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus recommendation of “Buy” by the eleven brokerages that are covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $58.20.

Several equities research analysts have commented on the stock. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, HC Wainwright boosted their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday.

Insider Transactions at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 7,489 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the transaction, the chief operating officer now directly owns 26,961 shares of the company’s stock, valued at $1,300,059.42. The trade was a 8.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,915 shares of company stock valued at $1,897,920 in the last 90 days. 22.87% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Mirum Pharmaceuticals by 16.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company’s stock valued at $3,055,000 after purchasing an additional 10,427 shares during the last quarter. Woodline Partners LP raised its stake in Mirum Pharmaceuticals by 22.2% in the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company’s stock valued at $16,722,000 after purchasing an additional 73,399 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $897,000. Finally, Tema Etfs LLC acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $1,735,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $47.57 on Friday. The firm’s fifty day moving average price is $46.96 and its 200 day moving average price is $43.40. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of -23.55 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million during the quarter, compared to analysts’ expectations of $96.64 million. On average, sell-side analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.